Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.

ABSTRACT: MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)¹. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition². Crizotinib is a multikinase inhibitor with potent activity against MET³. The antitumor activity and safety of crizotinib were assessed in 69 patients with advanced NSCLCs harboring MET exon 14 alterations. Objective response rate was 32% (95% confidence interval (CI), 21-45) among 65 response-evaluable patients. Objective responses were observed independent of the molecular heterogeneity that characterizes these cancers and did not vary by splice-site region and mutation type of the MET exon 14 alteration, concurrent increased MET copy number or the detection of a

SUBMITTER: Drilon A 

PROVIDER: S-EPMC8500676 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature